- Price is above the Trend Line, keeping the weekly tape constructive.
- Volume is elevated versus the 13-week average, confirming attention.
- Latest weekly return ranks in the strongest part of its sector group.
ALTME
PAR
Week ended 21 Aug 2026
Weekly Investor Report
TME Pharma N.V. · Healthcare · Biotechnology
Latest close
0.0892 EUR
39.4%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 20.8% above the Trend Line and sits at 57.3% of its 52-week range. The latest completed week returned 39.4%, after a 44.3% four-week move. The latest news-sentiment score is 50/100.
Setup score
54
out of 100
Latest Close
0.0892 EUR
21 Aug 2026
1W Return
39.4%
latest completed week
4W Return
44.3%
short-term follow-through
12W Return
3.6%
quarterly tape
Trend Breadth
32.7%
17 of 52 weeks active
Volume Ratio
10.4x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Next-week expectancy is negative at 39.33% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
39.4%
Latest completed week; four-week move 44.3%.
Indicator stack
18/44
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 39.33%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
1 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 20.8% above the Trend Line and sits at 57.3% of its 52-week range. The latest completed week returned 39.4%, after a 44.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 10.4x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.3012-week average 0.41
12-week confirmation
Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.30Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 44.3% over four weeks, 3.6% over 12 weeks, and -18.2% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year17
Trend breadth32.7%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.53Latest activity-pressure read.
Pressure change41.7%Four-week change in activity pressure.
Leadership10.74Latest relative-leadership reading.
RS change141.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 1 relevant articles.
0 positive · 1 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-25.2%Distance below the 52-week high.
13-week volatility11.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
27 Feb
27 Mar
24 Apr
22 May
19 Jun
17 Jul
21 Aug
Weeks higher11 of 2614 weeks finished lower.
Best week+39.4%Week of 21 Aug.
Worst week-9.0%Week of 10 Jul.
Latest week+39.4%Week of 21 Aug.
Shape of recent returns
Strong gains5
Modest gains6
Flat weeks1
Modest losses7
Sharp losses7
Recent vol11.8%13-week weekly-return volatility.
Base vol8.5%52-week weekly-return volatility.
Up/down split23/28Count of positive and negative weeks in the 52-week window.
Average skew6.6% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorFR Healthcare
4-week rank3 / 76
Group average13.6%
Trend breadth32.9%
Trend32.9%active weekly trend signals
MD47.4%positive activity pressure
RS31.6%positive relative leadership
Four-week leaders
IndustryFR Biotechnology
4-week rank2 / 33
Group average26.7%
Trend breadth33.3%
Trend33.3%active weekly trend signals
MD51.5%positive activity pressure
RS33.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape45/100
Trend, activity pressure, participation, and risk combine to a 45/100 tape read.
Indicator analysis35/100Latest 12-week confirmation: trend 5/12, activity pressure 5/12, relative leadership 1/12.
Activity pressure 0.30; No reversal markers Next-Week ExpectancyNegative 39.33%Next-week expectancy is negative with a 39.33% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 1 relevant articles.
TME Pharma Publishes 2024 Financial Results and Provides Operating Update Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 21 Aug 2026 | 0.0892 EUR | 39.4% | 0.0738 EUR | 0.1814 EUR | -0.53 | 10.74 | 13.4M | Off |
| 14 Aug 2026 | 0.064 EUR | 2.4% | 0.073 EUR | 0.19 EUR | -1.05 | -22.45 | 735.5K | Off |
| 7 Aug 2026 | 0.0625 EUR | -0.2% | 0.0729 EUR | 0.1987 EUR | -1.14 | -25.91 | 305.5K | Off |
| 31 Jul 2026 | 0.0626 EUR | 1.3% | 0.0729 EUR | 0.2072 EUR | -1.10 | -25.07 | 232.4K | Off |
| 24 Jul 2026 | 0.0618 EUR | -2.8% | 0.0731 EUR | 0.2147 EUR | -0.91 | -25.86 | 652.5K | Off |
| 17 Jul 2026 | 0.0636 EUR | -5.2% | 0.0732 EUR | 0.2224 EUR | -0.76 | -24.32 | 87.7K | Off |
| 10 Jul 2026 | 0.0671 EUR | -9.0% | 0.0731 EUR | 0.23 EUR | -0.40 | -21.09 | 115.9K | Off |
| 3 Jul 2026 | 0.0737 EUR | 4.7% | 0.0729 EUR | 0.2382 EUR | 0.32 | -15.90 | 32.9K | On |
| 26 Jun 2026 | 0.0704 EUR | -4.0% | 0.0727 EUR | 0.2446 EUR | 0.97 | -19.29 | 103.1K | On |
| 19 Jun 2026 | 0.0733 EUR | -7.1% | 0.0726 EUR | 0.2513 EUR | 1.66 | -16.60 | 59.3K | On |
| 12 Jun 2026 | 0.0789 EUR | -3.3% | 0.0724 EUR | 0.259 EUR | 2.11 | -9.84 | 210.2K | On |
| 5 Jun 2026 | 0.0816 EUR | -5.2% | 0.0724 EUR | 0.2669 EUR | 1.93 | -5.50 | 172.8K | On |
| 29 May 2026 | 0.0861 EUR | 6.6% | 0.0724 EUR | 0.2747 EUR | 1.60 | -0.08 | 587.6K | On |
| 22 May 2026 | 0.0808 EUR | 2.3% | 0.0728 EUR | 0.2823 EUR | 1.25 | -5.49 | 1.7M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.